Search results for "Salami"

showing 10 items of 28 documents

Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications.

2007

Inflammatory bowel diseases (IBDs) such as Crohn’s disease and ulcerative colitis are the result of an imbalanced mucosal T cell response. Despite the identification of a genetic susceptibility region in the NOD2/CARD15 (nucleotide-binding oligomerisation domain 2/caspase recruitment domain 15) gene, the aetiology is still unclear. Thus, the hunt for disease-initiating factors such as defects in the mucosal barrier or pathogenic microorganisms is ongoing. By contrast, the immunopathogenesis in IBDs is better understood. The identification of cytokines that are involved in T cell and monocyte signalling led to specific therapeutic concepts. Recent data have clearly shown that the most powerf…

Programmed cell deathNecrosisCell Survivalmedicine.medical_treatmentT cellT-LymphocytesApoptosisImmune systemCrohn DiseaseNOD2AzathioprinemedicineHumansIntestinal MucosaMesalamineImmunity Mucosalbusiness.industryInterleukin-6Tumor Necrosis Factor-alphaAnti-Inflammatory Agents Non-SteroidalGastroenterologyRecent Advances in Basic ScienceInflammatory Bowel DiseasesInterleukin-12Immunosuppressive drugmedicine.anatomical_structureApoptosisImmunologyTumor necrosis factor alphamedicine.symptombusinessImmunosuppressive AgentsSignal TransductionGut
researchProduct

HSP10,HSP70 AND HSP90 IMMUNOHISTOCHEMICAL LEVELS CHANGE IN ULCERATIVE COLITIS AFTER THERAPY

2011

Ulcerative colitis (UC) is a form of inflammatory bowel disease (IBD) characterized by damage of large bowel mucosa and frequent extra-intestinal autoimmune comorbidities. The role played in IBD pathogenesis by molecular chaperones known to interact with components of the immune system involved in inflammation is unclear. We previously demonstrated that mucosal Hsp60 decreases in UC patients treated with conventional therapies (mesalazine, probiotics), suggesting that this chaperonin could be a reliable biomarker useful for monitoring response to treatment, and that it might play a role in pathogenesis. In the present work we investigated three other heat shock protein/molecular chaperones:…

HistologyBiophysicsDown-RegulationInflammationcomorbidity.Inflammatory bowel diseaseulcerative colitis heat shock proteins Hsp molecular chaperones inflammation comorbidity.Pathogenesischemistry.chemical_compoundMesalazineulcerative colitis heat shock proteins Hsp molecular chaperones inflammation comorbidityHeat shock proteinChaperonin 10MedicineHspHumansHSP70 Heat-Shock ProteinsHSP90 Heat-Shock ProteinsColitisMesalaminelcsh:QH301-705.5ulcerative colitisbusiness.industryBrief Reportmolecular chaperonesAnti-Inflammatory Agents Non-SteroidalCell Biologymedicine.diseaseUlcerative colitisImmunohistochemistrydigestive system diseaseschemistrylcsh:Biology (General)inflammationImmunologyheat shock proteinsBiomarker (medicine)Colitis Ulcerativemedicine.symptombusiness
researchProduct

Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on topical therapy in ulcerative colitis

2020

Although most patients with ulcerative colitis should be given topical treatment, different studies have shown that they are underused in clinical practice. The purpose of this article is to answer 10 specific questions about which drugs are available for topical use in the treatment of ulcerative colitis, and their characteristics in terms of formulation, dosage, presentation, application and proximal distribution of rectal-administered drugs. The efficacy of available topical drugs and the benefits of combining different formulations and routes of administration, and their usefulness during disease remission are evaluated. Finally, a series of recommendations addressed to patients are giv…

glucocorticoidesmedicine.medical_specialtycolitisAdministration TopicalhumanosAnti-Inflammatory AgentsTopical treatmentmesalamina03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMesalazineTopical treatmentmedicineMesalazinaHumansCorticosteroidsMesalamineGlucocorticoidsCrohn's diseasebusiness.industryAnti-Inflammatory Agents Non-Steroidalmedicine.diseaseantiinflamatoriosUlcerative colitisDermatologyClinical PracticechemistryUlcerative colitis030220 oncology & carcinogenesisDisease remission030211 gastroenterology & hepatologyColitis UlcerativeMesalazinebusiness
researchProduct

The production of typical cured meats from cattle of Cinisara breed

2019

In recent years consumers prefer genuine, tasty, protein-rich, low in fat and cholesterol products. The Cinisara cow is a dairy Sicilian autochthonous breed, reared in the western part of the isle according to the traditional livestock system, based on grazing natural pastures. The meat of Cinisara cattle could be used to obtain also processed products, among which salami and bresaola, as commercial alternatives to fresh meat, in order to increase the economic profitability of farms. The aim of this research was to produce bresaola and salami with meat from adult cows (AC) and grazing (GB) or housed (HB) young bulls of Cinisara breed, evaluating their physico-chemical and sensory traits. In…

Settore AGR/19 - Zootecnica Specialebresaola and salami productiongrazingCinisara cow breedchemical and fatty acid composition
researchProduct

Is 5-ASA Still the Treatment of Choice for Ulcerative Colitis?

2010

5-Amino-salacylic acid (5-ASA) is up to now the treatment of choice in the induction and maintenance of remission of mild-to-moderate ulcerative colitis (UC). Sulfasalazine, despite similar efficacy, is hampered by more side effects, but in presence of peripheral arthopaties it remains the treatment of choice. The new delayed release MMX formulation seems to be promising in reducing compliance problems, but further studies are warranted to show the superiority of new MMX formulation compared with the older formulations of 5-ASA. Some trials evaluated also the efficacy and safety of once-daily dosing of older 5-ASA formulations in maintenance of remission, finding a greater adherence to ther…

medicine.medical_specialtySettore MED/09 - Medicina InternaClinical BiochemistryPharmacologyPlaceboSulfasalazineInternal medicineDrug DiscoverymedicineHumansDosingColitisMesalamine5-ASA Treatment Choice Ulcerative ColitisPharmacologyClinical Trials as Topicbusiness.industryAnti-Inflammatory Agents Non-Steroidalmedicine.diseaseUlcerative colitisTacrolimusRegimenMolecular MedicineColitis UlcerativeRosiglitazonebusinessmedicine.drugCurrent Drug Targets
researchProduct

« L’héritage de Salamina »

2005

International audience

[ SHS.HIST ] Humanities and Social Sciences/History[SHS.ART]Humanities and Social Sciences/Art and art history[ SHS.ART ] Humanities and Social Sciences/Art and art history[SHS]Humanities and Social Sciencesguerre civile espagnolemémoireSoldados de Salamina[SHS.HIST] Humanities and Social Sciences/History[ SHS ] Humanities and Social Sciencesadaptation cinématographique[SHS.ART] Humanities and Social Sciences/Art and art history[SHS] Humanities and Social Sciences[SHS.HIST]Humanities and Social Sciences/HistoryComputingMilieux_MISCELLANEOUS
researchProduct

Increased expression of markers of early atherosclerosis in patients with inflammatory bowel disease.

2016

Recent studies documented an increased cardiovascular risk in patients with inflammatory bowel disease (IBD). Our study aimed at investigating the prevalence of intima-media thickness (IMT) of the carotid arteries and the arterial stiffness indices as markers of early atherosclerosis in young IBD patients.We recruited 68 consecutive IBD patients, and 38 matched healthy controls less than 45years old (median age 31.6±8.1years). Clinical and demographic features, cardiovascular risk factors, history of cardiovascular events, concomitant therapies were registered on a dedicate database. Carotid IMT was evaluated by using high resolution B-mode ultrasonography. Arterial stiffness was assessed b…

AdultMalemedicine.medical_specialtyIBD030204 cardiovascular system & hematologyPulse Wave AnalysisInflammatory bowel diseaseCarotid Intima-Media ThicknessCarotid intima-media thickne03 medical and health sciencesYoung Adult0302 clinical medicineVascular StiffnessCrohn DiseaseRisk FactorsInternal medicineInternal MedicinemedicineHumansMesalaminePulse wave velocityTriglyceridesSubclinical infectionCrohn's diseasebiologybusiness.industryC-reactive proteinAnti-Inflammatory Agents Non-SteroidalCholesterol HDLCholesterol LDLmedicine.diseaseAtherosclerosisInflammatory Bowel DiseasesArterial stiffneBlood pressureCarotid ArteriesCholesterolIntima-media thicknessCase-Control StudiesImmunologyEarly atherosclerosiArterial stiffnessCardiologybiology.protein030211 gastroenterology & hepatologyColitis UlcerativeFemalebusinessBiomarkersEuropean journal of internal medicine
researchProduct

Preliminary results on the donkey salami made in Sicily

2009

In a dairy jennet farm the meat, which can be produced using the foals in excess, could be another profitable income. Equine meat is very thin and with high protein content; above all, the fatty acids are unsaturated, being a monogastric animal product. The donkey meat processed products are sold in niche market and are very appreciated by the European consumers. A study on the characteristics of the donkey salami made in Sicily was carried out using a 12 months old foal derived from Ragusano breed. Two different mixes were compared: only donkey meat (A thesis) and donkey meat plus the 10% of Nero Siciliano pig fat (AS thesis). The meat was husked of fat and nerves and mixed with 3.5 kg/q o…

Settore AGR/19 - Zootecnica SpecialeDonkey meatSalami Chemical composition weight decrease
researchProduct

Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.

2016

IF 10.383; International audience; OBJECTIVES: Cancer may be a complication of inflammatory bowel disease (IBD) or its treatment. In elderly onset IBD patients the risk of malignancy is of particular concern. We studied this risk in a population-based cohort of elderly onset IBD patients.METHODS: In a French population-based cohort, we identified 844 patients aged >60 years at IBD diagnosis from 1988 to 2006, including 370 Crohn's disease (CD) and 474 ulcerative colitis (UC). We compared incidence of cancer among IBD patients with that observed in the French Network of population-based Cancer Registries (FRANCIM). Confidence interval (CI) was estimated assuming a Poisson-specific law for ra…

MESH: CarcinomaMaleNonmelanoma Skin-CancerInflammatory bowel disease0302 clinical medicineAdrenal Cortex HormonesAzathioprineMESH: IncidenceAge of OnsetAged 80 and overeducation.field_of_studyMESH: Middle AgedRheumatoid-ArthritisIncidenceGastroenterologyMESH: Follow-Up StudiesMESH: Anti-Inflammatory Agents Non-Steroidal3. Good health030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatology[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Immunosuppressive Agentsmedicine.medical_specialtyMESH: Age of OnsetMESH: Colitis Ulcerativedigestive systemMESH: Adrenal Cortex Hormones03 medical and health sciencesIntestinal NeoplasmsHumansCrohns-DiseaseeducationMESH: Intestinal NeoplasmsMESH: Protective FactorsMESH: AzathioprineAgedRetrospective StudiesMESH: HumansMESH: Crohn DiseaseTumor Necrosis Factor-alphaMESH: Retrospective Studiesmedicine.diseaseMESH: Inflammatory Bowel DiseasesInflammatory Bowel Diseasesdigestive system diseasesLymphoproliferative DisordersMethotrexateMESH: Tumor Necrosis Factor-alphaColitis UlcerativeComplicationMESH: FemaleProspective Observational CohortTime FactorsMESH: RegistriesMESH: Proportional Hazards ModelsMaintenance TherapyMESH: Aged 80 and overMESH: Lymphoproliferative DisordersCrohn DiseaseMESH: Risk FactorsRisk FactorsNeoplasmsMESH: NeoplasmsRegistriesUlcerative-ColitisMesalamineMESH: AgedIncidence (epidemiology)Anti-Inflammatory Agents Non-SteroidalMetaanalysisMiddle AgedhumanitiesMESH: MethotrexateFemaleFranceFrench PopulationColorectal NeoplasmsImmunosuppressive AgentsMESH: Myeloproliferative DisordersPopulationColorectal-CancerIncreased RiskInternal medicinemedicineProportional Hazards ModelsMyeloproliferative DisordersHepatologybusiness.industryMESH: Time FactorsCarcinomaCancerRetrospective cohort study[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: MesalamineProtective FactorsMESH: MaleMESH: FranceAge of onsetbusinessMESH: Colorectal NeoplasmsFollow-Up StudiesThe American journal of gastroenterology
researchProduct

Double Drug Delivery Using Capped Mesoporous Silica Microparticles for the Effective Treatment of Inflammatory Bowel Disease

2019

[EN] Silica mesoporous microparticles loaded with both rhodamine B fluorophore (S1) or hydrocortisone (S2), and capped with an olsalazine derivative, are prepared and fully characterized. Suspensions of Si and S2 in water at an acidic and a neutral pH show negligible dye/drug release, yet a notable delivery took place when the reducing agent sodium dithionite is added because of hydrolysis of an azo bond in the capping ensemble. Additionally, olsalazine fragmentation induced 5-aminosalicylic acid (5-ASA) release. In vitro digestion models show that S1 and S2 solids are suitable systems to specifically release a pharmaceutical agent in the colon. In vivo pharmacokinetic studies in rats show …

MaleHydrocortisoneTECNOLOGIA DE ALIMENTOSReducing agentPharmaceutical Science02 engineering and technologyMesoporous silica microparticles030226 pharmacology & pharmacyInflammatory bowel diseaseSodium dithionite03 medical and health scienceschemistry.chemical_compoundHydrolysisDrug Delivery Systems0302 clinical medicineQUIMICA ORGANICAIn vivoDrug DiscoveryQUIMICA ANALITICAmedicineRhodamine BAnimalsGated materialsRats WistarMesalamineOlsalazineRhodaminesColon targeted releaseQUIMICA INORGANICAMesoporous silicaColitisInflammatory Bowel DiseasesSilicon Dioxide021001 nanoscience & nanotechnologySmart drug delivery materialsRatschemistryDrug deliveryMolecular Medicine0210 nano-technologymedicine.drugNuclear chemistry
researchProduct